This is a live, so it's scrappy, but the sound should be good! :)

We are joined by our GLP-1 social media news correspondents, Maria Rising and Sabina Hemmi from GLP Winner, to get the latest updates on GLP-1, from the big pharma lawsuits to the states trying to reduce access or ban compound GLP-1.

Washington HB 2613 (going to committee on Jan 30th - you can sign up to testify or submit written testimony)
Mississippi SB 2544:

Other bills I mentioned:
Indiana SB 282:
Florida SB 877, HB 860
Virginia HB 917

Send us Fan Mail!

Support the show

Kim Carlos, Executive Producer

TikTok

Instagram

Kat Carter, Producer

TikTok

Instagram

Resources for the Community:

___________________________________________________________________

https://linktr.ee/theplussidez

Find Your US Representatives

https://www.usa.gov/elected-officials

______________________________________________________________________

This isn’t medical advice — always talk to your doctor before making any health decisions.

“What do I eat in a day?” is one of the most common and most searched questions people ask when starting a GLP-1. In this episode, we’re joined by Ana Reisdorf, MS, RD, registered dietitian and host of the GLP1 Hub Podcast, to explore how nutrition support fits into GLP-1 treatment in the real world. We talk through Ana’s lived experience with weight, the difference between dietitians and nutritionists, and why many patients are left without practical guidance once a prescription is written.

The conversation focuses on the growing gap between physician time constraints and patient needs, and how dietitians who understand and support GLP-1s are uniquely positioned to bridge it. We break down macros in accessible terms, discuss nutritional balance beyond protein, and examine how resting metabolic rate, sleep, appetite regulation, and tracking all influence daily intake, especially for those with a history of food or body trauma. This episode highlights why GLP-1-informed dietitians may play a central role in the future of sustainable, patient-centered obesity care.

Professional/Community Guest:

Ana Reisdorf MS, RD

GLP1 Hub Podcast

Links

GLP1Hub Podcast

Apple Podcast

Spotify

YouTube

Website

Instagram

______________________________________________________________________

#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide #GLP1 #Obesity #zepbound #wegovy #ObesityCare #PatientAdvocate #GLP1Community #

Send us Fan Mail!

Support the show

Kim Carlos, Executive Producer

TikTok

https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc

Instagram

https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr

Kat Carter, Associate Producer

TikTok

https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc

Instagram

https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Linktree for Community Resources
https://linktr.ee/theplussidezpodcast

_________________________________________________________________________

In this episode, we break down the latest GLP-1 news around policy and legal developments impacting access to compounded GLP-1 medications in the United States.

We’re joined by special news correspondents Sabina Henn, an obesity advocate from GLPWinner.com, and Maria Rising, a GLP-1 reporter on TikTok and obesity advocate. Both are deeply involved in obesity care advocacy and work on and off the internet to protect patient access to treatment.

We begin with the broader national strategy shaping current GLP-1 policy, then walk through key federal and state actions, including the SAFE Drug Act (SR 6509), Indiana SB 282, and Florida SB 860 / HB 877. We explain how these bills could restrict access to compounded GLP-1 medications and why that poses a serious problem for patients who cannot take brand-name drugs or cannot afford them due to lack of insurance coverage and high costs.

We also cover the ongoing lawsuits between GLP-1 drug manufacturers and compounding pharmacies, including the Strive lawsuit, and examine the use of racketeering claims as a legal strategy. Throughout the episode, we focus on the real-world impact of these actions and how they could affect millions of patients relying on compounded GLP-1 medications for obesity and metabolic disease care.

We close with clear ways listeners can stay informed, engage, and help protect access to care.

Lawsuit Tracker
https://docs.google.com/spreadsheets/d/1XoaPEVWv5AxUJyoluaD-eExTPHK3GClIiV0xyI9rXqc/edit?usp=sharing

Follow Sabina:
Tiktok: https://www.tiktok.com/@lawliepop?lang=en
Instagram: https://www.instagram.com/glpwinner/
X: https://x.com/lawliepop?lang=en
YouTube: https://www.youtube.com/ ⁨@lawliepop⁩

Follow Maria
TikTok
https://www.tiktok.com/@tirzepatidetales?_r=1&_t=ZP-93ELkA5nG9e
Substack
https://substack.com/search/tirzepatidetales?searching=profile

_________________________________________________________________________

Join this channel to get access to perks:
https://www.youtube.com/channel/UC0HUIGKl3BN4Vg6LYI-dkOA/join

_________________________________________________________________________
#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide #GLP1 #Obesity #zepbound #wegovy #GLP1News

Send us Fan Mail!

Support the show

Kim Carlos, Executive Producer

TikTok

Instagram

Kat Carter, Producer

TikTok

Instagram